title: Measles and rubella antibody status in children after treatment for acute lymphoblastic leukemia.
abstract: OBJECTIVE
  To assess the vaccination history and the status of vaccine-induced protection from measles and rubella in children after treatment for acute lymphoblastic leukemia.
  
  
  METHODS
  Measles and rubella immunological status was assessed by the ELISA technique for 22 children previously treated for acute lymphoblastic leukemia.
  
  
  RESULTS
  From the total of 22 patients, 20 had been given two doses of measles vaccine and 18 had had one dose of rubella vaccine. The percentage of patients seropositive for measles and rubella were 65 and 88.9%, respectively, with no correlation with age of patient, aggression of treatment or the time passed between the end of treatment and sample collection.
  
  
  CONCLUSIONS
  We detected that vaccination had failed against measles and rubella in 35 and 11.1% of cases, respectively. We recommend that a measles booster be given after the completion of treatment for acute lymphoblastic leukemia and that rubella immunity status should be assessed at this point, with revaccination performed when necessary.
authors.affiliation: Departamento de Pediatria, Faculdade de Medicina, Universidade de São Paulo (USP), São Paulo, SP, Brazil.
authors.forename: Sáhlua M
authors.initials: SM
authors.lastname: Volc
authors.forename: Maria T A
authors.initials: MT
authors.lastname: Almeida
authors.forename: Márcia D
authors.initials: MD
authors.lastname: Abadi
authors.forename: Ana Lucia
authors.initials: AL
authors.lastname: Cornacchioni
authors.forename: Vicente
authors.initials: V
authors.lastname: Odone Filho
authors.forename: Lílian M
authors.initials: LM
authors.lastname: Cristofani
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology; D007115:Immunization Schedule; D008457:Measles / Q000276:immunology* / Q000517:prevention & control; D008458:Measles Vaccine / Q000276:immunology*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000276:immunology*; D012409:Rubella / Q000276:immunology* / Q000517:prevention & control; D012411:Rubella Vaccine / Q000276:immunology*; D018709:Statistics, Nonparametric
chemical_list: D000970:Antineoplastic Agents; D008458:Measles Vaccine; D012411:Rubella Vaccine